Beautiful Virgin Islands

Tuesday, Jun 24, 2025

David Beckham-backed cannabis firm sparks investor rush on eve of public float

David Beckham-backed cannabis firm sparks investor rush on eve of public float

SYNTHETIC cannabinoid company Cellular Goods has seen 13 applications for each one of the 260 million shares on offer when it officially launches on the London Stock Exchange.

The tidal wave of interest from institutional and, unusually, retail investors has lifted the market capitalisation of the London pioneer - which counts David Beckham as an early backer - to £25million in advance of the IPO, expected on Friday.

The firm is the latest in a number of companies in the cannabis space to go public following a ruling by regulator the Financial Conduct Authority to allow such businesses to list on the main exchange.

But it has one major difference: the legal cannabis component on which its ranges of sports pain relief and skincare products will be made is entirely synthetic, manufactured in laboratories.

Founder and CEO Alexis Abraham said the decision, which will prove pivotal to the company’s operations and fortunes, came about by “happy accident” as the firm prepared to predict and navigate the legal and regulatory hurdles associated with bringing a novel product - and one based on a classified drug - onto the market.

He told the Standard: “We took the decision from the get-go that we would engage with the FCA with the LSE from day one and work with them.

“Once you’ve got past the general question of legality you get very quickly into the next question about THC [the illegal active component of cannabis]. That’s not an issue because you make the undertaking that you will never bring a product to market that hasn’t been tested.

“But then you get to the much more thorny issue of POCA [the Proceeds of Crime Act], which essentially says that even if something is explicitly legal in the UK, the manner in which it was produced has a material impact on the legality of the end product.

“So let’s say you are a company in the UK bringing out a natural CBD product which, say, comes from Portugal and it’s being extracted from the flowers and leaves of the plant.

“In the UK you are only permitted to extract from the stalk. It’s an archaic legal requirement that dates back to the use of hemp, but it has been badly repurposed to try and cover a nascent new industry which is not fully understood by the regulator.

“They are coming on in leaps and bounds and we have seen incredible engagement with the industry but of all the other companies operating in this space, I don’t think anyone else went down the biosynthetic rabbit-hole.

“And the nice thing about going down that rabbit hole to solve the POCA issue was that we discovered this technology that was mind-blowingly better.”
‘The next generation of this technology could give us cannabinoid vending machines’

CG has built up relationships with manufacturing laboratories in California who are all competing to produce and refine platforms which synthesise cannabinoids.

Abraham said: “Even now now we are looking at seven days to produce one batch versus about 200 days for the equivalent field-grown. On top of that you are using probably 1/200th of the energy and water, you have no issues around pesticide taint or contaminants. It’s not just a slightly better process - it’s an order of magnitude better.

“And the next generation of this technology could practically give us cannabinoid vending machines. We feel the cannabis boom will never come. It’s going to be about cannabinoids and fermentation is the future.”

The company was founded by Abraham in 2018 after previous roles in brand development and digital strategy and now employs eight people full-time at its London hub working in partnerships with labs and manufacturers around the world.

Money raised from the sale will be plowed into development and marketing of a range of products for skin care and sports recovery, with the first due to launch in September.

All of the initial ranges, at least, will be topical treatments - lotions and oils which are rolled or sprayed onto the skin and not ingested.

A skincare product will exploit CBD’s reputed anti-bacterial, antioxidant and anti-inflammatory properties.

Early next year, a second range of sports recovery roll-ons products will come on the market.

Abraham said: “There’s a huge amount of anecdotal evidence that it seems to have benefits. We are not going after any kind of medical claim at this stage, we are not going to the medical space.

“We want to make a product that does not just target elite athletes and everyday gym-goers but everybody. Everybody should be able to move a little bit better whether they are 18 or 80.”

The sports link brought CG into contact with investors working for David Beckham’s investment vehicle DB Ventures early on.

Keen to enter the space, but wary of any potential controversy and regulatory issues, CG’s clinical means of production lent immediate appeal.

While Beckham himself has been hands-off so far, and there is no intention of the football star fronting ad campaigns, his experience may well be drawn upon to help to shape the firm’s future development. DBV has retained a 5% stake.

At present, CG remains a tight-knit outfit, with just eight employees co-ordinating research, development and marketing.

Abraham said: “It was important to us not to follow that model of becoming a big bloated business and just hiring for the sake of hiring. We have the mentality of start-up combined with access to capital and agility of a listed company.

“In a way, we are a company was built to be born during the pandemic. We are all used to the Zoom calls now. We did the investor roadshow virtually, between eight and 10 calls a day for two weeks, dealing with high net worth institutions.

“As the sessions went on it grew more exciting, you could feel the interest building and as people went from being curious to understanding the depth of the people we have in Alexia [Blake, head of research and development] and the advisory board.”

CG does not rely on farmed plants

Another key difference from the recent launches of medicinal marijuana vape-maker Kanabo and biopharma firm MGC Pharma, which is developing epilepsy and dementia drugs, is that the IPO has been opened up to retail investors.

Of the 260 million shares on offer, 52% of its total, 68 million have been allocated to 6,000 private investors at 5p a share in an arrangement co-ordinated through the PrimaryBid platform, an official partner of the LSE which connects companies to communities of potential buyers.

The move comes among growing complaints from major retail investment platforms that traders are being locked out of blockbuster floats by institutional investors and investment banks, and missing out on the initial price fizz that has come to accompany such launches in today’s frothy equity markets.

The decision also goes to the heart of the company’s philosophy of the relationship it wants to foster with its customers.

Abraham accepted that the move has made the IPO more complicated - even 48 hours beforehand the final timing of launch is still to be rubber-stamped by the LSE and FCA.

He said: “PrimaryBid have been an exceptional partner, and what they’re doing is to bring the necessary strictures and clarity to what is unquestionably a complicated process. There is an element of truth in the suggestion that bringing more investors is complicated, but it’s also an asset that other people don’t bother to tap into.

“I’ve had 2,000 emails since we started this retail process, a lot with thoughts and advice on how they see the company working, and what they find interesting.

“It’s very rare in my experience that you don’t learn something from your customers and if they are willing to volunteer information freely it’s incredible. We sent out a survey to everyone involved in the retail offer and we’ve had over 2,000 response already. almost 80% have never tried cannabinoids before but they were fascinated by the space.

Another thing that resonated with me about why go retail we have an unusually accessible share price. It’s not like we are saying you can buy one share or maybe a fraction of a share.

“At 5p, for the price of one of the skincare products they can have a 100 shares and with some luck and us doing a good job of it, that will be worth something.

“There’s a really interesting story about not just owning the products but owning a piece of the company. Of course there will be people in it for a quick dollar but I hope that as many people as possible get in at the beginning and stay with us for the journey.”

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
BBC Demands Perplexity AI Immediately Stop Using Its Content
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
Political Turmoil Resurfaces in Belgium Amid Economic Concerns
Fed policymakers divided on timing of interest rate cuts
Trump signals imminent agreement with Harvard University
Inheritance tax referendum alarms Swiss billionaire community
Japan cancels bilateral security meeting amid US defence demands
AI skeptic Emily Bender warns that ‘the emperor has no clothes’
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
Plans to Sell Dutch Embassy in Bangkok Face Local Opposition
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump's $5 Million 'Trump Card' Visa Program Draws Nearly 70,000 Applicants
DGCA Finds No Major Safety Concerns in Air India's Boeing 787 Fleet
Airlines Reroute Flights Amid Expanding Middle East Conflict Zones
Elon Musk's xAI Seeks $9.3 Billion in Funding Amid AI Expansion
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Taiwan Imposes Export Ban on Chips to Huawei and SMIC
Israel has just announced plans to strike Tehran again, and in response, Trump has urged people to evacuate
Netanyahu Signals Potential Regime Change in Iran
Juncker Criticizes EU Inaction on Trump Tariffs
EU Proposes Ban on New Russian Gas Contracts
×